An open-label, dose-escalation, phase I study to determine the maximum tolerated dose, recommended dose, pharmacokinetics, and pharmacodynamics of the proteosome inhibitor CEP 18770 given intravenously as single agent in patients with advanced solid tumours or non-Hodgkin's lymphomas

Trial Profile

An open-label, dose-escalation, phase I study to determine the maximum tolerated dose, recommended dose, pharmacokinetics, and pharmacodynamics of the proteosome inhibitor CEP 18770 given intravenously as single agent in patients with advanced solid tumours or non-Hodgkin's lymphomas

Completed
Phase of Trial: Phase I

Latest Information Update: 21 May 2010

At a glance

  • Drugs Delanzomib (Primary)
  • Indications Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 21 May 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
    • 21 May 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Jan 2009 Planned end date changed from 1 Jun 2009 to 1 Dec 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top